1. Are there specific restrictions on the indication of YFV in patients with CIMID baseline disease, activity, or medication use facing a yellow fever outbreak? | |
2. Is the risk of SAE following primary or booster YFV vaccination higher in patients with CIMID? Is this related to disease type or activity? | |
3. Is the risk of SAE following primary and booster YFV vaccination higher in patients using corticosteroid or CsDMARD, TsDMARD or JAK inhibitors? | |
4. Is the risk of SAE after primary or booster YFV vaccination higher in patients with CIMID using immunosuppressive drugs (azathioprine, cyclophosphamide, cyclosporine, mycophenolate mofetil/acid) or bDMARD? | |
5. Should an interval be recommended between YFV application (primary or booster) and initiation or restart of medications for CIMID treatment? | |
6. Should a minimum interval be recommended between discontinuation of medications for CIMID treatment and YFV application (primary or booster)? | |
7. Does the concomitant application of other vaccines interfere in the YFV response in patients receiving or not CIMID treatment? | |
8. Is there any contraindication of YFV in close contacts or people living with CIMID patients? | |
9. Does the use of immunomodulatory and/or immunosuppressive agents in patients with CIMID interfere in the YFV response or long-term efficacy? |